Abbott Laboratories 8-K details stock plan blackout, trading limits

Rhea-AI Filing Summary

Abbott Laboratories reported that its U.S. and Puerto Rico stock retirement plans will undergo an administrative blackout period. The blackout is being implemented to make several plan administration changes, including switching the recordkeeper, changing the trustee for certain U.S. Plan funds, and changing the custodian for certain P.R. Plan funds.

During the blackout, participants in these plans will not be able to change contribution rates, reallocate or diversify investments

Abbott also notified its directors and executive officers about the blackout and related restrictions on trading in Abbott common shares under Section 306 of the Sarbanes-Oxley Act and Regulation BTR. Additional information about the blackout, including its actual start and end dates, is available on request from Abbott for two years after it ends.

false 0000001800 Common Shares, Without Par Value ABT 0000001800 2025-11-18 2025-11-18 0000001800 us-gaap:CommonStockMember exch:XCHI 2025-11-18 2025-11-18 0000001800 us-gaap:CommonStockMember exch:XNYS 2025-11-18 2025-11-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

Common Shares, Without Par Value ABT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

November 18, 2025

Date of Report (Date of earliest event reported)

ABBOTT LABORATORIES

(Exact name of registrant as specified in charter)

Illinois		1-2189		36-0698440
(State or other Jurisdiction		(Commission File Number)		(IRS Employer
of Incorporation)				Identification No.)

100 Abbott Park Road

Abbott Park, Illinois 60064-6400

(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code:  (224) 667-6100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨        Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨        Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨        Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨        Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered Pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol(s)	Name of Each Exchange   on Which Registered
Common Shares, Without Par Value	ABT	New York Stock Exchange NYSE Texas

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

Item 5.04 Temporary Suspension of Trading Under Registrant’s Employee Benefit Plans

On November 18, 2025, Abbott Laboratories (“Abbott”) received a notice from the plan administrator of the Abbott Laboratories Stock Retirement Plan (“U.S. Plan”) and the Abbott Laboratories Stock Retirement Plan (Puerto Rico) (“P.R. Plan”; collectively, the “Plans”) pursuant to Section 101(i)(2)(E) of the Employee Retirement Income Security Act of 1974 regarding a blackout period (the “Blackout Period”) under the Plans. The Blackout Period is required because the Plans are making certain administrative changes, including changing the recordkeeper, changing the trustee for certain funds of the U.S. Plan, and changing the custodian of certain funds of the P.R. Plan.

During the Blackout Period, Plan participants will be unable to engage in transactions involving the assets held in their Plan accounts, including changing contribution rates, directing or diversifying investments (including investments in Abbott common shares), or obtaining a Plan loan, withdrawal, or distribution.

As described more fully in the Notice (as defined below), the Blackout Period is expected to begin on December 24, 2025 at 12 p.m. CST and expected to end during the week of January 11, 2026. During the Blackout Period and for two years after the ending date of the Blackout Period, a security holder or other interested person may obtain, without charge, information regarding the Blackout Period, including the actual beginning and ending dates of the Blackout Period, by submitting a request to Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064, Attn: Divisional Vice President, Compensation and Benefits; (224) 667-6100.

On November 21, 2025, Abbott sent a notice to its directors and executive officers (the “Notice”) informing them of the Blackout Period and the restrictions on trading in Abbott common shares that apply to them during the Blackout Period, pursuant to Section 306 of the Sarbanes-Oxley Act of 2002 and Rule 104 of Regulation BTR. A copy of the Notice is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference.

Item 9.01 Financial Statements and Exhibits

Exhibit No. Exhibit

99.1 Notice provided to directors and executive officers of Abbott Laboratories on November 21, 2025.

104 Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ABBOTT LABORATORIES
Date: November 21, 2025	By:	/s/ Philip P. Boudreau
		Philip P. Boudreau
		Executive Vice President, Finance and Chief Financial Officer

FAQ

What did Abbott Laboratories (ABT) announce in this Form 8-K?

Abbott Laboratories announced a temporary blackout period for the Abbott Laboratories Stock Retirement Plan and the Abbott Laboratories Stock Retirement Plan (Puerto Rico) while these plans implement administrative changes, including changes to the recordkeeper, trustee, and custodian for certain funds.

When is the Abbott (ABT) retirement plan blackout period scheduled?

The blackout period for the Abbott U.S. and Puerto Rico stock retirement plans is expected to begin on December 24, 2025 at 12 p.m. CST and to end during the week of January 11, 2026, as described in the participant notice.

What restrictions will apply to Abbott retirement plan participants during the blackout?

During the blackout period, participants will be unable to change contribution rates, direct or diversify investments (including in Abbott common shares), or obtain plan loans, withdrawals, or distributions from their plan accounts.

How does the blackout affect Abbott (ABT) directors and executive officers?

Abbott sent a notice to its directors and executive officers explaining that, under Section 306 of the Sarbanes-Oxley Act and Rule 104 of Regulation BTR, they face restrictions on trading in Abbott common shares during the blackout period.

How can investors or participants get more information about the Abbott blackout period?

For two years after the blackout ends, security holders and other interested persons may request information, including the actual beginning and ending dates of the blackout, by contacting Abbott Laboratories at 100 Abbott Park Road, Abbott Park, Illinois 60064, Attn: Divisional Vice President, Compensation and Benefits, or by calling (224) 667-6100.

Does this Abbott (ABT) filing announce any major transaction or financial results?

No. The filing focuses on an administrative blackout period for Abbott’s stock retirement plans and related trading restrictions for directors and executive officers, rather than on financial results or major corporate transactions.